Search
for
Sort by
Research 31–60 of 518
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Pharmacotherapy of alopecia areata
- Ritlecitinib: First Approval
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Janus kinase inhibitors for alopecia areata: A narrative review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients